ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 619.1 | 544.5 | 840.4 |
| Other income | -1.8 | 6.2 | 12.1 |
| Total income | 617.3 | 550.7 | 852.5 |
| Profit before exceptional items & tax | 36.4 | 45.5 | 176.7 |
| Exceptional items | 16.5 | 4.9 | 15.8 |
| Profit before tax | 19.9 | 40.6 | 160.9 |
| Net profit | 8.3 | 29.0 | 117.2 |
| Operating margin | 3.2% | 7.4% | 18.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -92.90% |
|---|---|
| Net profit, quarter on quarter | -71.40% |
| Revenue, year on year | -26.30% |
NSE results filing, NSE: COHANCE. Figures extracted from the filing.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹460.10
- Market cap
- ₹17,604 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 371.6×Sector 43.8×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Capital Structure Change
Jasti group entities transferred 51,00,000 Cohance shares to Jasub Property Holdings LLP via inter-se block deals. Combined group holding remains 6.36%.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Cohance Lifesciences Management Change
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Cohance Lifesciences Investor Presentation: Key Takeaways
Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.